Clinical Trials
11 trialsNCT05231629 2026-05-13
MASTER-2
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06679829 2026-04-24
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06207799 2026-02-19
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05031897 2025-10-30
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Phase 2 Recruiting
NCT03016806 2025-10-10
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
Recruiting
NCT06523699 2025-08-28
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
Phase 1 Recruiting
NCT04483206 2025-05-31
Personalized Autologous Transplant for Multiple Myeloma
Emory University
Phase 1 Recruiting
NCT06140966 2025-04-16
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06245629 2024-11-29
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Uppsala University
Recruiting
NCT05636787 2024-07-08
TreoMel
Insel Gruppe AG, University Hospital Bern
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting